The number of people with susceptibility test result for rifampicin in Estonia
Estonia: The number of people with susceptibility test result for rifampicin was 96.1 in 2021. ▬ Flat
Latest (2021)
96.1
Change on year
up 0.3%
World rank
48th
of 146 countries
All-time high
100
in 2019
All-time low
95.79
in 2020
Years of data
5
2017–2021
The number of people with susceptibility test result for rifampicin in Estonia, 2017–2021
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for the number of people with susceptibility test result for rifampicin in Estonia is 96.1, measured in 2021.
Compared with earlier readings it is up 0.3% on the previous year and down 3.1% over five years.
That places Estonia 48th out of 146 countries with data for 2021, putting it in the middle of the range.
The number of people with susceptibility test result for rifampicin in Estonia, year by year
| Year | Value | Change |
|---|---|---|
| 2017 | 99.19 | — |
| 2018 | 99.05 | -0.1% |
| 2019 | 100 | +1.0% |
| 2020 | 95.79 | -4.2% |
| 2021 | 96.1 | +0.3% |
Estonia compared with similar countries
- Estonia's 96.1 is above the median for high income countries, which is 92.6, 1.0× the median. (56 countries reporting)
- Estonia's 96.1 is above the median for Europe & Central Asia, which is 93.52, 1.0× the median. (43 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2010s | 99.41 | 99.05 | 100 | 3 |
| 2020s | 95.95 | 95.79 | 96.1 | 2 |
Countries ranked near Estonia
More health data for Estonia
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -1.02 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,416 deaths per 1,000 people (2090)
- Number of infants who die before age 1 3 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate -6.8 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.021 units per person (2025)
- Population ages 00-04, male, annual growth rate -6.34 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is the number of people with susceptibility test result for rifampicin in Estonia?
- The number of people with susceptibility test result for rifampicin in Estonia was 96.1 in 2021, according to World Health Organization, Global Health Observatory.
- What is the highest the number of people with susceptibility test result for rifampicin recorded in Estonia?
- The highest recorded value was 100 in 2019.
- What is the lowest the number of people with susceptibility test result for rifampicin recorded in Estonia?
- The lowest recorded value was 95.79 in 2020.
- How does Estonia rank for the number of people with susceptibility test result for rifampicin?
- Estonia ranks 48th out of 146 countries with data for 2021.
- Where does this Estonia data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of The number of people with susceptibility test result for rifampicin among bacteriologically confirmed pulmonary TB patients expressed as percentage.. Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 5 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).